Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Teva
Colorcon
Boehringer Ingelheim
AstraZeneca
Citi
Farmers Insurance
Harvard Business School
US Army

Generated: January 16, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021411

« Back to Dashboard

NDA 021411 describes STRATTERA, which is a drug marketed by Lilly and is included in one NDA. It is available from five suppliers. Additional details are available on the STRATTERA profile page.

The generic ingredient in STRATTERA is atomoxetine hydrochloride. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the atomoxetine hydrochloride profile page.
Summary for 021411
Tradename:STRATTERA
Applicant:Lilly
Ingredient:atomoxetine hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021411
Medical Subject Heading (MeSH) Categories for 021411
Suppliers and Packaging for NDA: 021411
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411 NDA Eli Lilly and Company 0002-3227 0002-3227-30 30 CAPSULE in 1 BOTTLE (0002-3227-30)
STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411 NDA Eli Lilly and Company 0002-3228 0002-3228-30 30 CAPSULE in 1 BOTTLE (0002-3228-30)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength5MG
Approval Date:Nov 26, 2002TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength10MG
Approval Date:Nov 26, 2002TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength18MG
Approval Date:Nov 26, 2002TE:ABRLD:Yes

Expired US Patents for NDA 021411

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-005 Nov 26, 2002 ➤ Sign Up ➤ Sign Up
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 ➤ Sign Up ➤ Sign Up
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-008 Feb 14, 2005 ➤ Sign Up ➤ Sign Up
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-002 Nov 26, 2002 ➤ Sign Up ➤ Sign Up
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-006 Nov 26, 2002 ➤ Sign Up ➤ Sign Up
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-004 Nov 26, 2002 ➤ Sign Up ➤ Sign Up
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-003 Nov 26, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Boehringer Ingelheim
Federal Trade Commission
Fish and Richardson
US Army
US Department of Justice
Cipla
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.